Currently out of the existing stock ratings of Benjamin Burnett, 97 are a BUY (63.4%), 55 are a HOLD (35.95%), 1 are a SELL (0.65%).

Benjamin Burnett

Work Performance Price Targets & Ratings Chart

Analyst Benjamin Burnett, currently employed at STIFEL, carries an average stock price target met ratio of 46.7% that have a potential upside of 33.7% achieved within 120 days.

Benjamin Burnett’s has documented 302 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FATE, Fate Therapeutics at 05-Mar-2025.

Wall Street Analyst Benjamin Burnett

Analyst best performing recommendations are on EFTR (EFFECTOR THERAPEUTICS).
The best stock recommendation documented was for CRSP (CRISPR THERAPEUTICS AG) at 2/13/2025. The price target of $49 was fulfilled within 1 day with a profit of $5.51 (12.67%) receiving and performance score of 126.7.

Average potential price target upside

of $103.1 (58.13%) on NLTX (NEOLEUKIN THERAPEUTICS).
of $36.14 (118.98%) on GBT (GLOBAL BLOOD THERAPEUTICS).
of $20.09 (49.37%) on ACLX (ARCELLX).

ALLO Allogene Therapeutics ATRA Atara Biotherapeutics BLUE Bluebird bio CRSP Crispr Therapeutics AG CTIC CTi Biopharma Corp DTIL Precision BioSciences FATE Fate Therapeutics GBT Global Blood Therapeutics IOVA Iovance Biotherapeutics MRTX Mirati Ther NKTR Nektar Therapeutics SGMO Sangamo Therapeutics PGEN Precigen IDYA Ideaya Biosciences RPTX Repare Therapeutics RVMD Revolution Medicines EFTR Effector Therapeutics GNCA Genocea Biosciences NLTX Neoleukin Therapeutics BEAM Beam Therapeutics KNTE Kinnate Biopharma ACLX Arcellx GRCL Gracell Biotechnologies IRON Disc Medicine

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brian Cheng (JPMORGAN)